Cipla strikes Serum deal to break into vaccines; Amgen opens biologics plant in Singapore;

@FiercePharma: ICYMI: This week's full issue of FiercePharmaMarketing. Subscribe here. | Follow @FiercePharma

@CarlyHFierce: U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. FierceVaccines article | Follow @CarlyHFierce

> India's Cipla has entered the vaccines space with a deal with the Serum Institute of India, whose low-cost pediatric vaccines it will market in Europe. More

> Amgen ($AMGN) has opened a $200 million continuous purification plant in Singapore. More

> Perrigo says it plans to sell $900 million in stock to fund its acquisition of Belgium's Omega Pharma. Report (sub. req.)

> Multinational pharmas are selling their drugs at higher prices in South Korea than in other countries, a report says. More

> AstraZeneca ($AZN) has priced a new debt issue of 750 million in euro-denominated notes. Report

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Medical marijuana company licenses RapidMist device for buccal delivery. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. Updated story | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off. More | Follow @VarunSaxena2

@EmilyWFierce: More on how the Cystic Fibrosis Foundation's deal with Royalty Pharma could affect R&D and patients. NYT story | Follow @EmilyWFierce

> Smith & Nephew closes a facility in the U.S., sells another in the UK, 100+ to be laid off. More

> New paradigms in diagnostics: graphene and a single drop of blood. Editor's Corner

> Molecular nuclear imaging startup to use $100M IPO to advance Phase III therapeutic. Article

Biotech News

@FierceBiotech: Success or failure, feds want trial results posted online. Article | Follow @FierceBiotech

@JohnCFierce: U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Important M&A code name update from @BloombergNews: $AGN was "Avocado" to $ACT and "Apollo" to $VRX. Article | Follow @DamianFierce

> U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine. Article

> Success or failure, feds want trial results posted online. More

> Sanofi sticks to Viehbacher's R&D script as it rolls out a $38B pipeline vision. Story

Vaccines News

> PATH chooses Mymetics for work on transmission-blocking malaria vax. Item

> U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. More

> Pfizer's MenB reach--and lead on Novartis--limited without ACIP nod. Report

> NewLink Ebola vaccine trial to start in Canada. Article

> Celldex glioblastoma vaccine extends survival in Phase II. Story

Pharma Manufacturing News

> Ranbaxy can't stop the FDA from yanking drug approvals over plant problems. Item

> Amgen opens $200M continuous purification plant in Singapore. Story

> Doc coughs up $2M for using unapproved Avastin on his cancer patients. Report

> Interpol: Organized crime, aware of weak points, targets counterfeit drugs. Story

> U.K. generics maker to build $31M plant in Alabama. Article

And Finally... The British government has launched a review to speed the path to market for new drugs. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.